Trellis

STRAIN-INDEPENDENT THERAPEUTIC ANTIBODIES FOR INFLUENZA

THERAPEUTIC ANTIBODY FOR RSV

THERAPEUTIC ANTIBODIES FOR CMV

THERAPEUTIC ANTIBODIES FOR BIOFILM INFECTIONS

THERAPEUTIC ANTIBODY FOR CMV

BIOFILM DISRUPTING ANTIBODY TO TREAT RESPIRATORY AND MUSCULOSKELETAL INFECTIONS

HCMV THERAPEUTIC ANTIBODY SAFETY TRIAL

ECONOMIC DEVELOPMENT INITIATIVE, COMMUNITY PROJECT FUNDING, AND MISCELLANEOUS GRANTS

FINANCIAL ASSISTANCE AWARD

THERAPEUTIC ANTIBODIES FOR BIOFILM INFECTIONS

FINANCIAL ASSISTANCE AWARD

THERAPEUTIC ANTIBODIES FOR RABIES

THERAPEUTIC ANTIBODIES FOR BACTERIA

LOW TRELLIS PRODUCTION, HARVESTING SYSTEM AND MARKETING TOOLS FOR LOCALLY-GROWN HOPS AND VALUE-ADDED PRODUCTS

MODULAR SHADING STRUCTURE FOR HIGH VALUE FRUITS AND VEGETABLES

MODULAR TRELLIS SYSTEM FOR BRAMBLES

BACTERIAL PNEUMONIA THERAPEUTIC ANTIBODY SAFETY TRIAL - ABSTRACT BIOFILM IS A MAJOR CONTRIBUTOR TO CLINICAL ANTIBIOTIC RESISTANCE, AS BIOFILM-ASSOCIATED (SESSILE) BACTERIA SHOW UP TO 1000-FOLD LOWER SENSITIVITY TO ANTIBIOTICS THAN FREE GROWING (PLANKTONIC) FORMS. THE CDC ESTIMATES THAT 70% OF CLINICALLY SIGNIFICANT ANTIBIOTIC FAILURE IS DUE TO BIOFILM, INCLUDING INFECTIONS ASSOCIATED WITH IMPLANTS, CATHETERS, AND TISSUE ADHESIONS. TRL1068 IS A NATIVE HUMAN MONOCLONAL ANTIBODY (MAB) THAT IS HIGHLY EFFECTIVE FOR DISRUPTING BIOFILM AND THEREBY ENHANCING THE BACTERICIDAL ACTIVITY OF CONVENTIONAL ANTIBIOTICS. THE ANTIBODY TARGET IS CONSERVED ACROSS BOTH GRAM POSITIVE AND NEGATIVE BACTERIA SPECIES. WITH PRIOR SBIR FUNDING, WE DEMONSTRATED EFFICACY IN FIVE RODENT MODELS. WITH CARB-X FUNDING, WE INITIATED CLINICAL DEVELOPMENT FOR PATIENTS WITH A PROSTHETIC JOINT INFECTION (PJI): TRL1068-101 (CLINICALTRIALS.GOV NCT04763759). STANDARD OF CARE FOR SUCH PATIENTS INCLUDES REPLACEMENT OF THE INFECTED IMPLANT WITH AN ANTIBIOTIC ELUTING SPACER FOR 8 WEEKS FOLLOWED BY A SECOND SURGERY TO IMPLANT A FRESH PROSTHESIS. A PLANNED INTERIM ANALYSIS DEMONSTRATED POSITIVE SAFETY DATA, AND ESTABLISHED THAT THE ANTIBODY PENETRATES INTO THE SYNOVIAL SPACE. THE BACTERIAL BURDEN ON THE EXPLANTED PROSTHESIS WAS QUANTIFIED FOLLOWING A STANDARDIZED SONICATION METHOD FROM THE MAYO CLINIC IN A STANDARDIZED VOLUME OF RINGER SOLUTION. AFTER 7 DAYS OF TREATMENT WITH TRL1068, 6 OF 8 PATIENTS (75%) HAD A BACTERIAL BIOFILM BURDEN BELOW 100 CFU/ML SONICATION FLUID, AND FOR 2 OF THEM THE ADHERENT BACTERIA WERE BELOW THE LIMIT OF DETECTION. THE REDUCTION AND REMOVAL OF BIOFILM IN THESE EIGHT PJI PATIENTS COMPARES FAVORABLY TO HISTORICAL DATA (N=60) FOR WHICH IMPLANTS FROM ONLY 15% OF PJI PATIENTS WERE BELOW 100 CFU/ML SONICATION FLUID. IN ONE OF THE ANIMAL MODELS ABOVE, TRL1068 WAS ADMINISTERED DIRECTLY TO THE RESPIRATORY SYSTEM AND WAS SHOWN TO BE EFFECTIVE FOR BACTERIAL PNEUMONIA. HERE, WE PROPOSE TO CONDUCT A PHASE 1 SAFETY TRIAL IN HEALTHY ADULT VOLUNTEERS FOR TRL1068 FORMULATED FOR NEBULIZED DELIVERY AS AN INHALED THERAPEUTIC TO TREAT BRONCHIAL INFECTIONS. WE HAVE PREVIOUSLY DEVELOPED AN INHALED FORMULATION FOR OUR INFLUENZA THERAPEUTIC MAB PROGRAM (NEAR-IND). DIRECT ADMINISTRATION OF TRL1068 TO THE AIRWAYS SHOULD PROVIDE SUPERIOR EFFICACY AT A SUBSTANTIALLY REDUCED DOSE.

TO EXPAND ON EXISTING SUCCESSFUL EFFORTS BY TRELLIS FOR TOMORROW ANDPARTNER ENTITIES TO IMPROVE FOOD JUSTICE AND FOOD SYSTEM SUSTAINABILITYBY DEVELOPING CLOSED LOOP FOOD SYSTEMS IN TWO URBAN CLUSTERS WITH HIGHPERCENTAGES OF PEOPLE FACING FOOD INSECURITY AND INADEQUATE ACCESS TOHEALTHY FOOD

THERAPEUTIC ANTIBODIES FOR BIOFILM INFECTIONS

LOW TRELLIS PRODUCTION AND HARVESTING SYSTEM FOR HOPS

MODULAR TRELLIS SYSTEM FOR BRAMBLES

AN ECONOMIC FEASIBILITY STUDY OF ESTABLI

THIS GRANT SUPPORTS THE COSTS INCURRED TO IMPLEMENT MEASURES TO RESPOND TO THE NOVEL CORONAVIRUS 2019 (COVID-19), WHICH MAY INCLUDE WORKPLACE SAFETY, MARKET PIVOTS, RETROFITTING FACILITIES, TRANSPORTATION, WORKER HOUSING, AND MEDICAL EXPENSES. IT PROVIDES NEEDED RELIEF TO THE FOOD PROCESSORS, DISTRIBUTORS, FARMERS MARKETS, AND PRODUCERS FOR THEIR COSTS INCURRED BETWEEN JANUARY 27, 2020, THE DATE UPON WHICH THE PUBLIC HEALTH EMERGENCY WAS DECLARED BY THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICE (HHS) UNDER SECTION 319 OF THE PUBLIC HEALTH SERVICE ACT, AND DECEMBER 31, 2021. BENEFICIARIES INCLUDE THE EMPLOYEES OF THE FOOD PROCESSORS, DISTRIBUTORS, FARMERS MARKETS, AND PRODUCERS.

THIS GRANT SUPPORTS THE COSTS INCURRED TO IMPLEMENT MEASURES TO RESPOND TO THE NOVEL CORONAVIRUS 2019 (COVID-19), WHICH MAY INCLUDE WORKPLACE SAFETY, MARKET PIVOTS, RETROFITTING FACILITIES, TRANSPORTATION, WORKER HOUSING, AND MEDICAL EXPENSES. IT PROVIDES NEEDED RELIEF TO THE FOOD PROCESSORS, DISTRIBUTORS, FARMERS MARKETS, AND PRODUCERS FOR THEIR COSTS INCURRED BETWEEN JANUARY 27, 2020, THE DATE UPON WHICH THE PUBLIC HEALTH EMERGENCY WAS DECLARED BY THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICE (HHS) UNDER SECTION 319 OF THE PUBLIC HEALTH SERVICE ACT, AND DECEMBER 31, 2021. BENEFICIARIES INCLUDE THE EMPLOYEES OF THE FOOD PROCESSORS, DISTRIBUTORS, FARMERS MARKETS, AND PRODUCERS.

SBIR PHASE I: IMPROVED SIGMA DELTA MODULATORS FOR RADIO FREQUENCIES